Ceribell 10-Q Details Q3: Revenue $29.3M, Loss Widens to $21.4M, Cash $117.5M
CBLL has more than doubled off its 52-week low of $10.85.
Summary
Ceribell's Q3 10-Q confirms 30% revenue growth to $29.3 million at a 90% gross margin, but the net loss widened to $21.4 million as operating expenses rose 36%. Cash stands at $117.5 million, debt now matures in 2031, and a key ITC patent ruling is due by November 19, 2026.
Key Events · Earnings and Guidance · CBLL
-
Q3 Revenue Grows 30% to $29.3M
Total revenue was $29.3 million versus $22.6 million a year earlier, with product revenue of $22.2 million (up 31%) and subscription revenue of $7.1 million (up 28%). Gross margin was 90% versus 88%.
-
Net Loss Widens on Launch Spend
Net loss was $21.4 million ($0.55 per share) versus $13.5 million ($0.37), as operating expenses rose 36% to $46.9 million; R&D jumped 49% to $7.4 million and sales and marketing rose 35% to $25.0 million.
-
Cash of $117.5M, Debt Pushed to 2031
Cash, cash equivalents and marketable securities totaled $117.5 million at September 30, 2026. The August 5, 2026 MidCap credit agreement provides a $30 million term loan commitment plus a $20 million revolver (upsizable to $30 million) maturing August 5, 2031, replacing the VLSA at a $1.5 million extinguishment loss.
-
Natus ITC Ruling Due November 19
Trial in the USITC patent case against Natus concluded June 12, 2026; an initial determination is expected by November 19, 2026 and a final determination by March 2027. The company carries a $2.9 million contingent deferred legal fee commitment, with no accrual recorded.
Analysis · CBLL · Industrial Applications And Services
The headline is 30% revenue growth at a 90% gross margin, but the full 10-Q reveals what that growth cost: operating expenses rose 36% to $46.9 million and the net loss widened to $21.4 million from $13.5 million a year ago, driven by a 49% jump in R&D and heavy sales hiring. Funding is not an immediate concern—the balance sheet still carries $117.5 million in cash and securities, and the August refinancing with MidCap pushed debt maturities out to 2031 while adding a $30 million undrawn term loan. Two items carry real event risk: an initial determination in the Natus ITC patent case is expected by November 19, 2026, and the CEO plus two directors adopted 10b5-1 selling plans on August 12, 2026 covering 472,500, 250,000 and 19,960 shares respectively.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CBLL was trading at $24.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $10.85 to $28.89. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.